Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension

LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek announced that the Journal of Ocular Pharmacology and Therapeutics published results from a Phase 2 study of the Company’s lead product candidate, trabodenoson, in patients with POAG or OHT.